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Blijham, P. J., H. J. ter Laak, H. J. Schelhaas, B. G. M. van
Engelen, D. F. Stegeman, and M. J. Zwarts. Relation between muscle
fiber conduction velocity and fiber size in neuromuscular disorders.
J Appl Physiol 100: 1837–1841, 2006. First published January 19, 2006;
doi:10.1152/japplphysiol.01009.2005.—To determine the relation be-
tween muscle fiber conduction velocity (MFCV) and muscle fiber diam-
eter (MFD) in pathological conditions, we correlated invasively measured
MFCV values with MFD data obtained from muscle needle biopsies in
96 patients with various neuromuscular disorders. MFCV was signifi-
cantly correlated with MFD and independent of the underlying disorder.
Pathological diameter changes were fiber-type dependent, with corre-
sponding MFCVs. A linear equation expresses the relation well: MFCV
(m/s)  0.043 MFD (m)  0.83. We conclude that fiber diameter
determines MFCV largely independent of the underlying neuromuscular
disorders studied.
electromyogram; muscle biopsy; muscle fiber potentials; propagation
velocity
THE PROPAGATION VELOCITY OF action potentials along nerve and
muscle fibers increases with increasing fiber diameter. In frog
muscle, a linear relationship between muscle fiber diameter
(MFD) and muscle fiber conduction velocity (MFCV) was found
by Ha˚kansson (5). For healthy human muscle fibers, the relation-
ship between MFCV and MFD was estimated from (separate)
literature data on fiber diameters and velocities as MFCV (m/s)
0.05 MFD (m) 0.95 (8). In various neuromuscular disorders,
MFCV is abnormal (1, 3, 14), which is generally ascribed to an
increased MFD variability (10), although sarcolemmal lesions and
fiber splitting may also influence MFCV (4). To date, no studies
on the intrasubject relation between MFCV and MFD in either
individual patients or healthy subjects are available.
The aim of the present study was to determine how MFCV
and MFD are related in subjects with various neuromuscular
diseases, possibly dependent on the pathophysiological char-
acteristics of the disease. A dependence on (a specific) disease
is a starting point for further investigating underlying causes,
whereas invariance would yield a method for predicting fiber
size from MFCV measurements in neuromuscular patients and
in muscle waste, e.g., in the elderly.
METHODS
Subjects. Patients with a clinical indication for a muscle biopsy
were asked to participate in this study. All subjects were seen by a
neurologist with neuromuscular expertise within the Neuromuscular
Centre Nijmegen before inclusion. After providing their informed
consent, they underwent a routine diagnostic workup, including lab-
oratory investigation, routine electromyogram (EMG), and muscle
biopsy. The final diagnosis, made by the neurologist, was based on the
clinical findings and the results of the diagnostic workup. Three
disease subgroups were defined, namely various noninflammatory
myopathies, inflammatory myopathies, and neurogenic diseases. The
study was approved by the University Hospital’s ethic committee and
was in adherence with the principles of the Declaration of Helsinki.
The generally preferred site for MFCV measurements was the
brachial biceps muscle, and for the biopsy it was the quadriceps
muscle. For the purpose of the study, the MFCV measurements and
the biopsy study were performed in the same affected muscle (bra-
chial biceps or quadriceps muscle) when clinical symptoms were
significantly different between the proximal leg and the arm muscles.
Measurement of MFCV. MFCV was measured with a Synergy
EMG system (Oxford Instruments, Surrey, UK), using a modified
invasive technique (1, 13). In short, a bundle of muscle fibers was
stimulated directly (stimulus strength, 2–10 mA; duration, 0.05 ms;
rate, 1 Hz), using a monopolar EMG needle electrode as cathode,
inserted at some distance from the end-plate zone along the fiber
direction, and a surface electrode as anode. A complex of propagating
single muscle fiber action potentials from a small bundle of stimulated
fibers was picked up with a concentric needle electrode (filter settings
500–10,000 Hz), inserted 45–55 mm proximal to the stimulating
needle electrode. Identical muscle fiber responses to five consecutive
stimuli were required to ensure reproducibility and to identify any
interfering responses caused by voluntary contraction (Fig. 1A). La-
tencies were measured to the positive peaks of a spike exceeding at
least 20 V in amplitude. Each latency value was transformed into a
velocity, using the distance, measured at the skin, between the points
of insertion of the stimulating and the recording electrode as estimate
of the propagated distance. MFCV was measured in at least five
different sites in the muscle, and the total number of muscle fiber
action potentials to be recorded in a patient was at least 25.
Muscle biopsy. After the MFCV measurements, three muscle
specimens (cylindrical in shape with a length of 1 cm and a radius of
0.5 cm maximally) were taken by a Bergstrom needle (length 15 cm)
biopsy from the superficial part of the biceps brachii or quadriceps
muscle (depth from skin to puncture place 3 cm). If the same muscle
was used for MFCV recording and biopsy, care was taken to insert the
biopsy needle at a site between the stimulation site and recording site
of the MFCV study. Specimens mostly contained200 muscle fibers.
One specimen per patient was taken for muscle fiber histochemistry
and enzyme histochemistry. These specimens were quickly frozen in
isopentane cooled by liquid nitrogen. Transverse sections (10 m
thick) were cut at minus 20°C in a cryostat and were stained for fiber
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typing (myofibrillar ATPase after preincubation at pH 4.2) so that type
I fibers (darkly stained) and type II fibers (lightly stained) could be
discerned.
Both the smallest and largest type I and type II fibers were drawn
using a drawing microscope. Each drawn fiber area was transformed
into a circle by hand using a template with several circular diameters.
The matching diameter served as the measure for fiber size (12). Thus
four muscle fibers per patient were measured, providing the smallest
and largest diameter for type I and type II fibers.
Analysis. For each patient, the slowest and fastest MFCV of the
population of fibers measured and the smallest and largest MFD were
used for the present analysis. Correlation between MFD and MFCV
values and the significance of the correlations were calculated by
linear regression analysis. The validity of a linear relation was
confirmed by counting runs, testing a significant deviation of the
regression line from linearity (using GraphPad Instat version 3.05).
Such linear regression analysis was performed for the whole data
set and for each subgroup separately, for data sets obtained from the
same muscle, and for data sets taken from a different muscle. As a
next step, the analysis was performed using the diameters of type I
fibers and of type II fibers separately. The significance of any
difference between the subgroups, between the measurements of the
same muscle, and between different muscles was determined by
multiple regression analysis. A linear contrast of a regression model
with the diameters of fiber type I and type II was constructed to
determine fiber-type influence on the measurements. A P value 
0.05 was considered significant.
RESULTS
Ninety-six patients older than 18 yr were included. Of these
subjects, 35 had a myopathy (4 patients had limb girdle
syndrome, 5 dystrophic myopathy, 2 steroid myopathy, 3
nemaline rod myopathy, 5 mitochondrial myopathy, 3 acid
maltase deficiency, 1 phosphorylase deficiency, 1 calcium-
ATPase deficiency, 11 aspecific myopathy), 21 had an inflam-
matory myopathy (13 patients had polymyositis, 5 dermato-
myositis, 3 inclusion body myositis), 1 had a neuromuscular
junction disorder, and 15 had a neurogenic disorder (10 pa-
tients had motoneuron disease, 1 chronic inflammatory demy-
elinating polyneuropathy, 1 spastic paraparesis, 3 unclassified
neuropathy). On the basis of the routine diagnostic workup,
one-fourth of the subjects (24) turned out not to have a
neuromuscular disorder. The male-to-female ratio was 1:2 in
the myopathies group and 1:1 in the other groups. Mean age
was 49  16 yr in the myopathies group, 56  4 yr in the
inflammatory myopathies group, and 56  16 yr in the neu-
rogenic group.
MFCV studies and biopsies were performed in the same
muscle in 53 subjects (24 in the brachial biceps and 29 in the
quadriceps muscle). In 43 subjects, MFCV was measured in
the brachial biceps, and the biopsy was taken in a different
muscle (39 in the quadriceps muscle, 1 in the deltoid, 1 in the
gastrocnemius, and 2 in the anterior tibial muscle). An example
of the MFCV measurements and a biopsy sample of the same
subject is given in Fig. 1.
The correlations between the smallest MFD and the slowest
MFCV, and between the largest MFD and fastest MFCV, are
given in Table 1. The correlations in the disease groups were
all significant, except for that for the largest MFD and the
fastest MFCV in the neurogenic group. The correlation be-
tween the smallest MFD and the slowest MFCV was signifi-
cantly higher (P 0.05) in the neurogenic subgroup than in the
myopathies subgroup. The scatterplots for the smallest MFD
and the slowest MFCV are presented in Fig. 2 for all subjects,
including the cases without a neuromuscular disease (A), and
separately for the myopathies group (B), the inflammatory
myopathies group (C), and the neurogenic group (D). Equiv-
alent scatterplots for the largest MFD and the fastest MFCV are
presented in Fig. 3. The data of the largest MFD and the fastest
MFCV in the myopathies group (Fig. 3B) contained one
outlier. The correlation between the largest MFD and the
fastest MFCV was significant in the whole group (P  0.001),
but not in the myopathies group, when this outlier was re-
moved from the analysis. None of the regressions deviated
Fig. 1. A: muscle fiber conduction velocity
study of a inflammatory myopathy patient.
Five traces are superimposed, showing an
identical response of several individual mus-
cle fiber potentials to 5 subsequent stimuli.
The fastest conduction velocity is 4.1 m/s
(L1) and slowest is 1.7 m/s (L2), illustrating
a wide range of velocities (distance of prop-
agation: 5 cm). B: detail of the quadriceps
muscle biopsy from the same patient, show-
ing a severe increase of muscle fiber diam-
eter variability (from extremely atrophic to
normal). Bar: 50 m (hematoxylin and
phloxine-stained frozen section).
Table 1. Correlation coefficients for the association between
the smallest muscle fiber diameter and the slowest muscle
fiber conduction velocity and between the largest muscle




All subjects 96 0.58† 0.46†
Measurements made in the same muscle 53 0.58† 0.58†
Measurements made in different muscles 43 0.60† 0.26
Myopathies 36 0.40* 0.46*
Neurogenic disorders 15 0.82† 0.27
Inflammatory myopathies 21 0.72† 0.47†
Rlow and Rhigh, correlation coefficients for the association between the
smallest muscle fiber diameter and the slowest muscle fiber conduction
velocity and between the largest muscle fiber diameter and the fastest muscle
fiber conduction velocity, respectively. *P  0.05. †P  0.0005.
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significantly from linearity. The correlation between smallest
MFD and slowest MFCV of measurements made in the same
muscle did not differ from measurements made in different
muscles (Fig. 4, A and B). The correlation between largest
MFD and fastest MFCV was significant if the measurements
were made in the same muscle, but not if they were made in
different muscles (Fig. 4, C and D).
In the whole group, mean smallest MFD of type II fibers was
significantly lower than that of type I fibers (P  0.001). Mean
largest MFD of type I fibers was significantly higher than that
of type II fibers (P 0.005). The regression model showed that
the slowest MFCV was mainly dependent on smallest type II
fibers, whereas the fastest MFCV was mainly dependent on
largest type I fibers.
Fig. 2. Scatterplots and regression lines of
the smallest muscle fiber diameter plotted
against the slowest conduction velocity for
all subjects (A; R  0.58) and for the groups
of patients with myopathies (B; R  0.40),
patients with inflammatory myopathies (C;
R  0.72), and patients with neurogenic
disorders (D; R  0.82), showing the corre-
lation between diameter and conduction ve-
locity.
Fig. 3. Scatterplot and regression line of the
largest muscle fiber diameter plotted against
the fastest conduction velocity for all sub-
jects (A; R  0.46) and for the groups of
patients with myopathies (B; R  0.46), pa-
tients with inflammatory myopathies (C; R
0.47), and patients with neurogenic disorders
(D; R  0.27), showing the correlation be-
tween diameter and conduction velocity.
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Figure 5 shows the combined data for the smallest MFD and
slowest MFCV and for the largest MFD and fastest MFCV. For
the whole data set, the best fitting linear equation was MFCV
(m/s)  0.043 MFD (m)  0.83. In the subgroups, this
equation was MFCV  0.043 MFD  0.90 in the myopathies
group, MFCV  0.042 MFD  0.70 in the inflammatory
myopathies group, and MFCV  0.049 MFD  0.53 in the
neurogenic group.
DISCUSSION
Our results show the validity of assuming a linear, albeit not
a proportional, relation between propagation velocity and fiber
diameter in vivo in neuromuscular patients. The relation found
for the whole population closely resembles the relation esti-
mated for normal healthy muscle (7). We found only small
differences between the different types of underlying neuro-
muscular disorder. The correlations remained significant if
measurements made in two different muscles were included,
suggesting a generalized disorder. The significant correlations
suggest that a minimum of 25 muscle fiber potentials as a
sample size is sufficient.
Relation between velocity and diameter. The “overall” rela-
tion between MFCV and MFD (MFCV 0.043 MFD 0.83)
in patients with a neuromuscular disease is remarkably similar
to that estimated for normal individuals (MFCV 
0.05 MFD  0.95) (8). This is the case, despite the fact that
the latter equation was based on MFCVs recorded from healthy
subjects in combination with independently obtained fiber
diameters taken from the literature, whereas our results are
based on an intrasubject observation of MFCV and MFD.
Despite the differences between the subgroups, discussed later,
overall a relative independence on pathological factors has
been found. This confirms the observations in membrane
simulation studies that, both in nerve and muscle fibers, con-
duction velocity depends mostly on fiber diameter, more than
on all the other factors implemented, even in myelinated nerve
fibers (7, 15). As suggested in the introduction, the relative
independence of secondary factors, next to diameter, indeed
opens the use of MFCV as a predictor of fiber size, not only in
patients but also in other applications where a noninvasive
determination of muscle fiber diameter can be important (e.g.,
in the elderly or in space physiology) (11).
Myopathies vs. neurogenic disease. The correlation between
the smallest MFD and the slowest MFCV was significant in the
myopathies group, although significantly lower than that in the
neurogenic group. The regression line was less steep, and the
y-intercept was higher (Fig. 2, B and D). The regression
Fig. 4. Scatterplots and regression lines of
the smallest muscle fiber diameter plotted
against the slowest conduction velocity for
samples taken in the same muscle (A; R  0.
58) and in different muscles (B; R  0.60)
and of the largest muscle fiber diameter plot-
ted against the fastest conduction velocity for
samples taken in the same muscle (C; R 
0.58) and in different muscles (D; R  0.26).
Fig. 5. Scatterplot of the associations between the smallest fiber diameter and
the slowest conduction velocity () and between the largest fiber diameter and
the fastest conduction velocity (■) for all patients. The solid regression line is
represented by the equation of muscle fiber conduction velocity 0.043  muscle
fiber diameter  0.83, and it was derived from our data. The dotted line
represents the relation suggested for normal muscle fibers [Nandedkar and
Sta˚lberg (8); muscle fiber conduction velocity  0.05  muscle fiber diame-
ter  0.95].
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equation for the neurogenic group came closer to that for
normal muscles than the equation for the myopathic group did.
This indicates that, for the smallest fibers, factors other than
fiber diameter have more influence on MFCV in myopathies
than they have in neurogenic disease or health.
One of these factors may be a lesion of the sarcolemma,
which has previously been suggested to disturb propagation (2,
4). Fiber splitting may be another contributing factor. It is
conceivable that in some myopathies, especially those charac-
terized by severe intracellular damage or extensive sarcolem-
mal degradation, the propagation of action potentials fails in an
early stage, before fiber atrophy.
In contrast to the correlation of the smallest MFD and the
slowest MFCV, the correlation between the largest MFD and
the fastest MFCV was significant in both myopathies group but
not in the neurogenic group. It seems that the smaller range of
maximal velocities and of thickest fibers in the neurogenic
group than in the other groups explains this finding. Or, from
a different perspective, the higher correlation between the
largest MFD and fastest MFCV in both myopathies group can
be explained by the presence of outliers (Fig. 3, B and C),
which were only found in the myopathies group. Although they
may be outliers statistically, they are not measurement arti-
facts. It is remarkable that, in a specific patient, the maximal
diameter was unmistakably 292 m, and the highest MFCV
was indeed 12 m/s. High MFCVs, up to 15.8 m/s, were also
measured in two other subjects, also in combination with (not
proportionally) hypertrophic fibers. So, high MFCVs do actu-
ally occur in the myopathic conditions, as a result of extreme
fiber hypertrophy. It should be noted that stimulation of a nerve
twig rather than the muscle fiber may lead to falsely high
MFCVs. This is further discussed in the Limitations of the
study section.
Type I fibers vs. type II fibers. The type II fibers showed
significantly more atrophy than the type I fibers, as has been
observed previously (2, 6). Fiber hypertrophy was significantly
more pronounced in type I fibers, which was expected because
these fibers are usually larger. This dependency of fiber type
and atrophy or hypertrophy resulted in a fiber-type dependency
of MFCV in the multivariance analysis. This implies that we
have measured the MFCV of either the slowest or fastest fiber
and that the measurement was independent of fiber type.
Influence of the site of measurements. Interestingly, the
correlation between the smallest MFD and the slowest MFCV
remained significant, even if the two measurements were made
in different muscles. The spectrum of muscle fiber sizes in
controls is quite different between the biceps (30–70 m) and
quadriceps (50–95 m) muscles (9). Fiber atrophy, however,
brings down the diameters to a small range in both muscles,
thus nullifying the initial difference. The correlation coeffi-
cients between the largest MFD and the fastest MFCV were
influenced by several outliers in the myopathies group, as
indicated before. If these outliers were removed, both correla-
tions were not significant. In contrast to atrophy, fiber hyper-
trophy may further amplify the difference between biceps and
quadriceps muscle fiber diameters in the upper range.
Limitations of the study. Although we established the appar-
ent relationship between the diameter and conduction velocity
of single muscle fibers in vivo, this relationship cannot be
verified on individual muscle fibers because it is technically
virtually impossible to measure propagation velocity and di-
ameter from one and the same fiber in vivo. Both MFD and
MFCV measurements were affected by sampling errors be-
cause only a small proportion of all fibers were measured;
unfortunately, it is not possible to determine the magnitude of
this sampling error.
Another, more minor, drawback of the technique for mea-
suring MFCV is uncertainty about the distance between the
stimulation and recording electrodes, which may especially be
a problem if fibers run skew with respect to the needle insertion
sites. As mentioned before, another pitfall of the method is the
possibility to stimulate nerve twigs instead of muscle fibers
directly. This gives rise to a potential with a different mor-
phology and preceding the direct fiber responses. It will also
invariably cause a gross muscle twitch, which can be used to
make the distinction with direct muscle fiber responses (13).
In conclusion, we have demonstrated that the relation be-
tween MFCV and MFD appears to be linear and that it closely
resembles a relation found in normal muscle. Only small
differences between myopathic and neurogenic disorders are
found with respect to this relation.
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